Souhaitez-vous accéder aux communiqués récents ?

Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.

Eli Lilly's (NYSE:LLY) strong Phase 3 results for Retevmo places the oncology community in the spotlight

Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. $NTHI, $ORKA, $ABVX, $SYRE

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla

The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare $HCWB, $TGNT, $MRNA, $REGN

The U.S. housing and construction sector may be entering its next major consolidation cycle

Advanced materials science sits at the intersection of biology, chemistry, and engineering. $KBLB, $LHX, $HXL, $AVNT, $ASPN

The performance limits of aircraft, body armor, medical devices, and even semiconductors are ultimately governed by the physical properties of the materia

Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of AI value creation may emerge: healthcare